case_images: PMC11106395_01
case_images: PMC11106395_02
case_images: Metabolic and radiologic evaluation on FDG-PET of cancer lesions throughout Phesgo  treatment. (A) Obtained on July 22, 2022; showed disease progression with an increased atypical lesion in the right breast and bilateral lymphadenopathies. (B) Captured on January 10, 2023; demonstrated a favorable response to Phesgo  treatment with reduced breast lesion size and improved lymphadenopathies. (C) Obtained on April 20, 2023; indicated disease progression with new hypermetabolic foci, pleural effusion, ascites, and lytic lesions.
case_images: fonc-14-1348343-g001.jpg
case_images: PMC11106395_02_fonc-14-1348343-g001.jpg
case_images: f1
case_images: After 6 months of therapy, and repeatedly thereafter, curative surgery was proposed, which the patient refused, maintaining trastuzumab and hormonal therapy up until July 2022, when after 30 months of therapy, locoregional, skin, pleural, peritoneal, and lymph node progression was confirmed ( Figure 1A ). In the first response evaluation by positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG), a partial metabolic response was documented with a clear decrease in the uptake in the breast lesion, the lymph nodes, and the pleural nodules, in addition to a decrease in the pleural effusion volume ( Figure 1B ). Figure 2 ). FDG-PET in April 2023 documented disease progression in the breast, pleura, peritoneum, and lymph nodes ( Figure 1C ).
case_images: Temporal evolution of clinical breast and skin lesions. A favorable clinical response was evident following the initiation of Phesgo in August 2022, with complete resolution of skin lesions observed by January 2023. However, upon completing 10 cycles of Phesgo by April 2023, there was a recurrence of skin lesions, concurrent with an increase in the size of the breast lesion and the identification of new left axillary lymphadenopathies.
case_images: fonc-14-1348343-g002.jpg
case_images: PMC11106395_02_fonc-14-1348343-g002.jpg
case_images: f2
case_images: Figure 2 ). FDG-PET in April 2023 documented disease progression in the breast, pleura, peritoneum, and lymph nodes ( Figure 1C ).